AU2001287040A1 - Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins - Google Patents

Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins

Info

Publication number
AU2001287040A1
AU2001287040A1 AU2001287040A AU8704001A AU2001287040A1 AU 2001287040 A1 AU2001287040 A1 AU 2001287040A1 AU 2001287040 A AU2001287040 A AU 2001287040A AU 8704001 A AU8704001 A AU 8704001A AU 2001287040 A1 AU2001287040 A1 AU 2001287040A1
Authority
AU
Australia
Prior art keywords
designing
methods
binding affinity
novel compounds
improved binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287040A
Inventor
Christopher D. Benjamin
Yen-Ming Hsu
Frederick R. Taylor
Zhongli Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU2001287040A1 publication Critical patent/AU2001287040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
AU2001287040A 2000-09-01 2001-08-31 Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins Abandoned AU2001287040A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23024200P 2000-09-01 2000-09-01
US23028000P 2000-09-01 2000-09-01
US60230280 2000-09-01
US60230242 2000-09-01
PCT/US2001/027360 WO2002018446A2 (en) 2000-09-01 2001-08-31 Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins

Publications (1)

Publication Number Publication Date
AU2001287040A1 true AU2001287040A1 (en) 2002-03-13

Family

ID=26924052

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287040A Abandoned AU2001287040A1 (en) 2000-09-01 2001-08-31 Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins

Country Status (4)

Country Link
US (2) US20030235861A1 (en)
EP (1) EP1314037A2 (en)
AU (1) AU2001287040A1 (en)
WO (1) WO2002018446A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4667383B2 (en) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Aglycosyl anti-CD154 (CD40 ligand) antibody and use thereof
EA014226B1 (en) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Anti-cd154 antibodies, fragments thereof and methods for using antibodies and fragments
BRPI0809042B1 (en) * 2007-03-22 2021-08-31 Biogen Ma Inc. ISOLATED CD154-BINDING PROTEIN, ITS USE, AND COMPOSITION
GB0721752D0 (en) * 2007-11-06 2007-12-19 Univ Southampton Configurable electronic device and method
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
SG10201606462WA (en) 2009-09-24 2016-09-29 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
LT2731973T (en) 2011-07-13 2018-02-26 Ucb Biopharma Sprl Bacterial host strain expressing recombinant dsbc
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2015017535A2 (en) * 2013-08-02 2015-02-05 Siemens Healthcare Diagnostics Inc. Cell-based control and method
US11275949B2 (en) 2014-02-28 2022-03-15 Second Spectrum, Inc. Methods, systems, and user interface navigation of video content based spatiotemporal pattern recognition
US20170269075A1 (en) 2014-05-12 2017-09-21 Biogen Ma Inc. Biomarkers predictive of lupus progression and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients

Also Published As

Publication number Publication date
US20060172346A1 (en) 2006-08-03
WO2002018446A2 (en) 2002-03-07
WO2002018446A3 (en) 2002-05-02
US20030235861A1 (en) 2003-12-25
EP1314037A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AU2001287040A1 (en) Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
AU3041100A (en) Binding of antibody fragments to solid supports
IL212419A0 (en) Methods of administering anti-tnf antibodies
AU2001294175A1 (en) Method of purifying antibody
AU2002354929A1 (en) Antibodies specific for nanotubes and related methods and compositions
AU2002366644A1 (en) Method for administering birb 796 bs
IL200608A0 (en) Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
AU2002361623A1 (en) Methods and compositions for chromatography
AU2002365258A1 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
AU3669199A (en) Methods of identifying and using hla binding compounds as hla-agonists and antagonists
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
WO2002049625A3 (en) Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
AU2002315066A1 (en) Methods for making antibody fragments and compositions resulting therefrom
AU2002364141A1 (en) Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof
AU2002365111A1 (en) Methods for identifying and using marr family polypeptide binding compounds
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2814200A (en) Compositions and methods for monitoring the modification of engineered binding partners
AU6922900A (en) High affinity dna binding compounds as adjuvants in antisense technology
AU2002226059A1 (en) Improved compositions and methods for producing antibodies to low molecular weight analytes
AU2002341068A1 (en) Method of identifying glycosyl transferase binding compounds
AU2002316178A1 (en) Compositions and methods for binding agglomeration proteins
AU2001284112A1 (en) Use of GRF1 protein for screening molecules
WO2001071346A3 (en) Binding compounds for cc chemokine receptor 5 and methods for identifying them
AU2002359281A1 (en) Identification of binding partners for specific proteins
AU2001260220A1 (en) Method for modification of proteins by transglutaminase